Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus hydroxychloroquine for advanced NSCLC (third-line)
ChiCTR2500113545Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of anlotinib and hydroxychloroquine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Progression-free survival. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
anlotinibhydroxychloroquine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500113545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113545.